相关实验视频
Updated: Jun 17, 2025
07:32
Murine Fecal Isolation and Microbiota Transplantation
Published on: May 26, 2023
4.0K
三甲基胺-氧化物和相关的肠道微生物衍生的代谢物和社区人口中的偶发心力衰竭发展
W H Wilson Tang1,2,3, Rozenn N Lemaitre4, Paul N Jensen4
1Department of Cardiovascular and Metabolic Sciences (W.H.W.T., Z.W., X.S.L., I.N., J.A.D.D., D.M., S.L.H.), Lerner Research Institute, Cleveland Clinic, OH.
Circulation. Heart failure
|August 9, 2024
概括
高水平的肠道微生物代谢物,如三甲基胺N氧化物和胆,与心力衰竭风险增加有关. 这项研究强调了肠道健康和心血管结果之间的联系.
科学领域:
- 心血管医学 心血管医学
- 微生物组研究 微生物组研究
- 代谢学 代谢学 代谢学
背景情况:
- 三甲基胺N氧化物 (TMAO) 是一种肠道微生物代谢物,与心血管疾病 (CVD) 和慢性病 (CKD) 风险有关.
- 对于TMAO及其相关代谢物 (胆,贝他因,卡尼丁,g-butyrobetaine,crotonobetaine) 对发生心力衰竭 (HF) 风险的具体影响尚未完全理解.
研究的目的:
- 调查TMAO和相关代谢物的循环度与发生HF的风险之间的关联.
- 在多元化,基于社区的队列中分析这些协会.
主要方法:
- 从心血管健康研究和动脉样硬化多民族研究中对11,768名参与者的聚合分析.
- 使用序列代谢物测量和考克斯比例危险模型.
- 经传统心血管疾病风险因素和功能调整.
主要成果:
- 在调整传统风险因素后,高度的TMAO,胆和克罗托诺贝他因独立地与高风险风险增加有关.
- 在对功能进行调整后,TMAO,胆和克罗托诺贝他因与HF风险之间的关联在统计学上并没有保持显著.
- 贝他因和卡尼丁显示名义关联与更高的HF发病率.
结论:
- 肠道微生物衍生代谢物的循环水平,包括TMAO,胆和克罗托诺贝他因,独立地与患HF的风险增加有关.
- 这些发现强调了肠道微生物组在HF病变发生过程中的潜在作用.
相关概念视频
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
69
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
69
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406